Title: Nuclex therapy for patients with chronic hepatitis C

Authors: Zenovii Y. Tkachuk; Valery M. Frolov; Yana A. Sotska; Oksana V. Kruglova

Addresses: Laboratory of Molecular Pharmacology, Institute of Molecular Biology and Genetics of Ukraine NAS, Kyiv, 150, Academica Zabolotnogo Str., Kyiv, 03680, Ukraine ' Department of Infectious Diseases and Epidemiology, Lugansk State Medical University, 91002, Lugansk-2, Post Office 2, Ukraine ' Department of Infectious Diseases and Epidemiology, Lugansk State Medical University, 91002, Lugansk-2, Post Office 2, Ukraine ' Department of Infectious Diseases and Epidemiology, Lugansk State Medical University, 91002, Lugansk-2, Post Office 2, Ukraine

Abstract: The three-month treatment with Nuclex and α-2b IFN in the complex therapy of the main group of CHC patients resulted in a positive dynamics in the clinical and immunological indicators and improvement in the functional status of the liver. The reference group of the patients, which received only α-2b IFN, also showed the positive dynamics of the analysed indicators, although to a much smaller degree as compared to the main group. The viral loads in the main group patients substantially dropped: the majority of the patients from the main group (78.6%) after the end of the treatment had minimal levels of the viral loads ranging (150-499) × 10³, while in some of the patients (10.7%) the virus was not detected at all. In the reference group, the treatment outcome was 4.5 times less than in the main group. The obtained results to allow consider the application of Nuclex in the complex therapy of CHC patients.

Keywords: chronic hepatitis C; CHC virus; HCV; treatment; nuclex therapy; interferons; IFNs; alpha-2b IFN; phagocytal activity; cytokines; viral loads; liver.

DOI: 10.1504/IJIS.2012.051236

International Journal of Immunological Studies, 2012 Vol.1 No.4, pp.349 - 364

Published online: 30 Aug 2014 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article